| Nov 7 |
Regulus Therapeutics GAAP EPS of -$0.21 misses by $0.04
|
| Nov 7 |
Regulus: Q3 Earnings Snapshot
|
| Nov 7 |
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
|
| Oct 29 |
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
|
| Oct 8 |
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
| Aug 14 |
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
|
| Aug 8 |
Regulus Therapeutics GAAP EPS of -$0.17 misses by $0.02
|
| Aug 8 |
Regulus: Q2 Earnings Snapshot
|
| Aug 8 |
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
|
| Aug 6 |
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
|
